Core Viewpoint - The successful issuance of the third phase of corporate bonds by Taizhou Huaxin Pharmaceutical Investment Co., Ltd. reflects the company's strong market position and the growing demand for its financial instruments [1] Group 1: Bond Issuance Details - The total scale of the bond issuance is 400 million yuan [1] - "25 Taihua 04" has an issuance scale of 150 million yuan, a 5-year term, and a coupon rate of 2.73%, with a subscription multiple of 4.6667 times [1] - "25 Taihua 05" has an issuance scale of 250 million yuan, a 10-year term, and a coupon rate of 3.75%, with a subscription multiple of 1.52 times [1] Group 2: Company Profile - Taizhou Huaxin Pharmaceutical Investment Co., Ltd. is the main entity for the development and construction of the health industry in Taizhou [1] - The company has a credit rating of AA+ and its main business includes revenue from product sales, real estate sales, and rental income [1] Group 3: Underwriter and Future Plans - Minsheng Securities, a subsidiary of Guolian Minsheng Securities, acted as the joint lead underwriter for this bond issuance [1] - Guolian Minsheng Securities aims to enhance financial service quality and efficiency, focusing on key regional development and resource allocation to support the real economy [1]